A role for the extracellular calcium-sensing receptor in cell-cell communication in pancreatic islets of Langerhans by Kitsou-Mylona, Isidora et al.
University of Warwick institutional repository: http://go.warwick.ac.uk/wrap
This paper is made available online in accordance with 
publisher policies. Please scroll down to view the document 
itself. Please refer to the repository record for this item and our 
policy information available from the repository home page for 
further information.  
To see the final version of this paper please visit the publisher’s website. 
Access to the published version may require a subscription. 
Author(s): Isidora Kitsou-Mylona, Christopher J. Burns1, Paul E. 
Squires2, Shanta J. Persaud, Peter M. Jones 
Article Title: A Role for the Extracellular Calcium-Sensing Receptor in 
Cell-Cell Communication in Pancreatic Islets of Langerhans 
Year of publication: 2008 
Link to published version: http://dx.doi.org/10.1159/000185540 
Publisher statement: None 
 
 1 
 A role for the extracellular calcium-sensing receptor in cell-cell communication in 
pancreatic islets of Langerhans. 
 
I Kitsou-Mylona, CJ Burns1, PE Squires2, SJ Persaud, PM Jones 
Beta Cell Development and Function Group, School of Biomedical and Health Sciences, 
King’s College London, Guy’s Campus, London SE1 1UL, UK 
1 Endocrinology Section, Biotherapeutics, NIBSC, Potters Bar, Hertfordshire, UK 
2Molecular Physiology, Biomedical Research Institute, Department of Biological 
Sciences, University of Warwick, UK 
 
Short title: Calcium sensing receptor and pancreatic β-cell function  
 
Corresponding author:  
Peter M Jones 
Beta Cell Development and Function Group 
Hodgkin Building (HB 2.10N) 
Guy’s Campus 
King’s College London 
London SE1 1UL 
 
Tel: +44 (0)207 848 6273 
Fax: +44 (0)207 848 6280 
e-mail: peter.jones@kcl.ac.uk 
Keywords: islet of Langerhans, pancreatic β-cell, calcium-sensing receptor, insulin 
secretion, proliferation  
 
 2 
Abstract 
Background: The extracellular calcium-sensing receptor (CaR) is expressed in many 
tissues that are not associated with Ca2+ homeostasis, including the endocrine cells in 
pancreatic islets of Langerhans.    We have demonstrated previously that 
pharmacological activation of the CaR stimulates insulin secretion from islet -cells and 
insulin-secreting MIN6 cells.  
Methods: In the present study we have investigated the effects of CaR activation on 
MIN6 cell proliferation and have used shRNA-mediated CaR knockdown to determine 
whether the CaR is involved in the regulation of insulin secretion via cell-cell 
communication.   
Results: CaR activation caused the phosphorylation and activation of the p42/44 MAPK 
signalling cascade, and this activation was prevented by the shRNA-induced down-
regulation of CaR mRNA expression.  CaR activation also resulted in increased 
proliferation of MIN6 cells, consistent with the known role of the p42/44 MAPK system in 
the regulation of -cell proliferation.  Down-regulation of CaR expression had no 
detectable effects on glucose-induced insulin secretion from MIN6 cells maintained as 
monolayers, but blocked the increases in insulin secretion that were observed when the 
cells were configured as three-dimensional islet-like structures (pseudoislets), consistent 
with a role for the CaR in cell-cell communication in pseudoislets.  
Conclusion: It is well established that islet function is dependent on communication 
between islet cells and the results of this study suggest that the CaR is required for β-
cell to β-cell interactions within islet-like structures.  
 3 
Introduction 
Islets of Langerhans form the minority (<5%) part of the mammalian pancreas where 
they comprise small (100-200 m) clusters of endocrine cells (3000-5000) that are 
scattered throughout the exocrine pancreas.  Insulin-expressing β-cells are the majority 
islet endocrine cell type (60-70%), but islets also contain glucagon-expressing -cells 
(10-20%), somatostatin-expressing -cells (~5%), low numbers of ghrelin- and 
pancreatic polypeptide-expressing cells, and a variety of non-endocrine cell types from 
the vasculature and immune system.  Individual islets are complex functional units which 
play a crucial role in regulating glucose homeostasis – loss of β-cells or failure of their 
secretory function results in the pathologies collectively known as diabetes mellitus. The 
mechanisms through which individual β-cells recognise and respond to extracellular 
signals are fairly well understood, but it is much less clear how interactions between islet 
cells regulate the integrated function of the islet as an endocrine unit. Intra-islet 
interactions are known to be essential for normal function: dispersal of islets into 
individual cells results in greatly reduced secretory responsiveness [1] which can be 
restored upon reaggregation of the cells into islet-like structures [1]. There are numerous 
potential mechanisms of intra-islet communication, including direct cell-cell contact via 
gap-junctions or cell adhesion molecules, and paracrine interactions via secreted 
agonists [2]. The heterogenous composition of a primary islet facilitates complex 
interactions between different cell types [2] but our studies using insulin-expressing 
MIN6 cells configured as islet-like structures [3, 4] suggest that homotypic interactions 
between β-cells are very important in the regulation of β-cell function. The current study 
addresses the possible role of the extracellular Ca2+-sensing receptor (CaR) in 
regulating islet function by acting as an intra-islet mechanism of homotypic 
communication between adjacent β–cells. 
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The CaR is a G-protein-coupled, seven transmembrane-spanning domain receptor 
which enables cells to detect and respond to changes in extracellular Ca2+ and other 
divalent cations [5]. CaR expression is traditionally associated with cells and tissues that 
are involved in the regulation of systemic Ca2+ levels, such as the parathyroid gland, 
kidney and bone, but it is now well established that the CaR is also expressed in cells 
that are not involved in Ca2+ homeostasis (e.g. oligodendrocytes [6], breast duct cells [7], 
fibroblasts [8], pancreatic acinar cells [9]), where it is associated with diverse functions 
including cell proliferation [6-8] and the regulation of secretion [9]. Our previous studies 
have shown that the CaR is expressed by islet β- and -cells, but not by -cells [10], and 
that pharmacological activation of the islet CaR using the calcimimetic A568 results in 
enhanced secretion of insulin and glucagon [11], suggesting an important function for 
CaR in regulating islet secretory function.  More recently, we have shown that CaR 
expression is regulated by the anatomical configuration of insulin-secreting β-cells, being 
up-regulated in dispersed cells, and down-regulated in cells configured as islet-like 
clusters (pseudoislets; [12]).  It has long been known that insulin secretory granules 
contain high concentrations of divalent cations (Ca2+, Mg2+, Zn2+) that are co-released 
with insulin on exocytosis of the  granule contents [13], and these divalent cations may 
reach sufficient local extracellular concentrations to activate the CaR [14, 10]. The 
localised presence within islets of high concentrations of extracellular cations and the 
CaR offers a potential novel mechanism of intra-islet communication. In the present 
study we have used shRNA-mediated CaR knockdown to investigate the role of the CaR 
in the regulation of islet function, focusing on β-cell proliferation and insulin secretion.  
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Materials and Methods 
Insulin-expressing MIN6 cells were obtained from Dr. Y. Oka and J.-I. Miyazaki (Univ. of 
Tokyo, Tokyo, Japan).   DMEM, glutamine, penicillin-streptomycin, gelatin (from bovine 
skin), PBS, foetal bovine serum and trypsin-EDTA were from Sigma-Aldrich (Poole, 
Dorset, U.K.).   RNeasy Mini RNA extraction kits were obtained from Qiagen (Crawley, 
West Sussex, U.K.).   PCR primers were prepared in-house (Molecular Biology Unit, 
King’s College London), and real-time quantitative PCR was performed using a 
LightCycler rapid thermal cycler system from Roche Diagnostics (Burgess Hill, West 
Sussex, U.K.). The colorimetric cell proliferation ELISA assay (Roche Diagnostics, 
Burgess Hill, West Sussex, U.K.) was used in this study to quantify cell proliferation. 
Polyacrylamide gels (10%), molecular mass markers, sample buffer, and PAGE buffers 
were from Invitrogen (Paisley, U.K.). The enhanced chemiluminescence (ECL) detection 
system and Hyperfilm were from GE Healthcare(Buckinghamshire, U.K.). The MEK 
inhibitors PD98059 and UO126 were from Calbiochem (Nottingham, UK). The 
calcimimetic A568 was from Amgen Inc (Thousand Oaks, CA, USA).  Rabbit polyclonal 
anti-ACTIVE® MAPK antibody was from Promega (Southampton, UK), and mouse 
monoclonal total p42/44 MAPK antibody was from Transduction Laboratories (BD 
Biosciences, Oxford, UK). Horseradish peroxidase (HRP)-conjugated goat anti-mouse 
IgG and goat anti-rabbit IgG were from Pierce Biotechnology (Rockford, IL, USA). The 
MISSION™ TRC shRNA kit (Sigma-Aldrich, St Louis, MO, USA) was used for the 
downregulation of CaR using lentiviral vectors. 
 
Cell culture and pseudoislet formation. MIN6 cells were maintained at 37oC / 5% CO2 in 
DMEM supplemented with FBS, penicillin / streptomycin, glutamine and G418, as 
described [3].. The medium was changed every 3 days and the monolayers were 
passaged or used for experiments when 70% confluent. MIN6 pseudoislets were 
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generated by culturing MIN6 cells for 7 days on tissue culture flasks that had been 
precoated with gelatin, as described previously [3]. 
 
Quantification of CaR mRNA levels 
Messenger RNA was isolated from MIN6 cells using the RNeasy Mini Kit according to 
the manufacturer’s instructions, mRNA was quantified using a Nanodrop spectrometer 
(NanoDrop, Rockland, ME) and cDNA was synthesised as described [15]. Mouse CaR  
forward and reverse PCR primers were as follows: forward,  5’-
CACTGCGGCTCATGCTTTCAC-3’, reverse, 5’-GCCTGGTGTCTGTTCAAAGTG-3’ 
(amplifies a fragment of 414bp).  Forward and reverse actin PCR primers were as 
follows: forward: 5’-ACG GCC AAG TCA TCA CTA TTG-3’; reverse: 5’-AGC CAC CGA 
TCC ACA CAG A-3’, the predicted size of the actin PCR product was 300bp. CaR 
standards ranging from 10 copies to 109 copies DNA were prepared as described [15]. 
Real-time PCR amplifications were performed using a LightCycler rapid thermal cycler 
system in a 10µl volume containing nucleotides, Taq DNA polymerase, and buffer (all 
included in the LightCycler FastStart Reaction Mix SYBR Green I; Roche Diagnostics, 
Burgess Hill, West Sussex, U.K ); template cDNA; 5mM MgCl2 and 0.5µM primers. All 
PCR protocols included an initial 10 min denaturation step and each cycle subsequently 
included a 95oC denaturation for 0s, annealing for 10s at 58oC (actin) or 61oC (CaR), 
and a 72oC extension phase for 14s (actin) or 25s (CaR). Fluorescence measurements 
were taken at 83oC (actin) or 85oC (CaR) for 3s to eliminate fluorescence from primer-
dimer formation. The amplification products of both primer pairs were subjected to 
melting point analyses and subsequent gel electrophoresis to ensure specificity of 
amplification. 
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Down-regulation of CaR expression in MIN6 cells 
The MISSION™ TRC shRNA kit was used to down-regulate CaR expression in MIN6 
cells. The manufacturers supplied five shRNA constructs targeting the mouse CaR 
mRNA, and appropriate control constructs. The sequences of the shRNA constructs 
were not supplied. MIN6 cells were seeded onto 96-well plates ata density of 20,000 
cell/well  and transduced according to the manufacturer’s instructions. Clonal selection 
of transduced cell was by puromycin (5μg/ml) resistance and expansion over 
approximately 30 days. In the current study clones were expanded after transduction 
with two CaR shRNA contructs (CaR2 and CaR4) and  control  clones were generated 
using lentiviral particles carrying  a shRNA construct that was not directed at the CaR 
(non-target control), or with lentiviral particles containing  an empty construct (non-
shRNA control). 
 
MAPK expression and activity  
Suspensions of MIN6 cells (1 x106 cells/500μl) were incubated (37oC, 5 min) in a 
physiological salt solution in the presence or absence of 1.3mM CaCl2  or A568 or the 
MEK inhibitors PD98059 and UO126.  Cells were pelleted by centrifugation (10000g, 
1min), the supernatant was discarded and protein extracts were prepared as described 
[11,16].  Proteins were separated by polyacrylamide gel electrophoresis, transferred to 
membranes and immunoprobed for p42/44 MAPK and for phosphorylated (activated) 
MAPK, as described [11,16].       
  
Cell Proliferation.  
DNA synthesis as a marker of cell proliferation was assessed by measuring the 
incorporation of 5-bromo-2’-deoxyuridine (BrdU) using two methods.  Measurements of 
the incorporation of BrdU into cell populations used a commercially available colorimetric 
 8 
assay kit, essentially according to the manufacturer’s instructions.  Briefly, MIN6 cells 
were seeded into 96-well microtitre plates at a density of 3,000 cells/well and were left to 
adhere overnight in a 37oC/ 5% CO2 incubator, followed by overnight incubation in 
serum-free culture medium containing 5.5mM glucose. Cells were subsequently 
incubated for 2.5 hours in serum-free culture medium containing 5.5mM glucose in the 
presence of 10μM BrdU and various concentrations of test agents.    Where the rate of 
proliferation was compared between monolayer and pseudoislet populations, the method 
was followed as previously described [17]. Measurements of BrdU incorporation into 
individual MIN6 cells used a microfluorimetric method to localise BrdU immunoreactivity 
in MIN6 cell nuclei, essentially as described previously [18]. Briefly, MIN6 cells were 
seeded onto 3-aminopropyl-triethoxysilane (APES) treated cover glass at a density of 
30,000 cells/well and left to adhere overnight under standard tissue culture conditions 
(95% CO2/5%O2; 37
oC) in DMEM supplemented with 15% FCS. Cells were then washed 
in sterile PBS and serum starved for 2hrs in fresh DMEM containing glucose (5.5mM) 
and nominal calcium (0.25mM) before a final 3hr incubation in media containing various 
concentrations of calcium (0, 0.5 and 2.5mM) and BrdU (10 M). Cells were fixed with 
4% paraformaldehyde and their DNA denatured using 1M HCl (30min at RT) before 
incubating in Alexa-594-conjugated anti-BrdU (Molecular Probes, Invitrogen) at 1:200 
and storing overnight at 4oC. After repeated washing (PBS /triton (0.01%)) BrdU 
incorporation was determined using an Axiovert 200 inverted fluorescent microscope 
(Carl Zeiss, Welwyn Garden City, UK). Six different wells were used for each treatment 
and the number of BrdU-positive cells counted in each sample exceeded 100cells/well.    
 
Insulin secretion  
Insulin secretion from MIN6 cells and MIN6 pseudoislets was measured using a 
multichannel perifusion apparatus maintained in a 37oC temperature controlled room, as 
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described previously [19-21].  Perifusate fractions were collected every 2 min and insulin 
and glucagon content, as appropriate, was determined by radioimmunoassay [22]. 
Statistical analysis of differences between secretory responses used the total areas 
under the curves in the perifusion experiments.   
 
Results   
CaR   down-regulation and coupling 
Quantitative RT-PCR analysis of MIN6 cell cDNA demonstrated the expression of CaR 
mRNA (Figure 1), confirming our previous report [12]. The data in Figure 1 also show 
that the CaR4 shRNA construct caused a marked down-regulation of CaR mRNA levels 
in the stably-transfected CaR4 MIN6 cell clone, whereas the CaR2 shRNA construct did 
not significantly reduce CaR mRNA expression. The shRNA-induced down-regulation in 
CaR mRNA expression resulted in decreased signalling through the CaR, as shown in 
Figure 2. In control MIN6 cells the phosphorylation and activation of p42/44 MAPK was 
induced by extracellular Ca2+ (1.3mM) in the presence or absence of the calcimimetic 
CaR agonist, A568 (0.1 M; Figure 1 A, B, lanes 3, 4), and this activation was blocked by 
the presence of pharmacological inhibitors of MAPK kinase (MEK; lanes 5,6, PD98059, 
UO126).  In the CaR4 MIN6 cells the stimulatory effects of Ca2+±A568 were greatly 
reduced (Fig.1 C, D lanes 3, 4), consistent with a down-regulation in functional CaR in 
these cells. The effect of CaR-downregulation to reduce p42/44 phosphorylation is also 
apparent in the immunoblots shown in Figure 1 panels E and F, in which extracts from 
control and CaR4 MIN6 cells have been loaded on to adjacent lanes to allow direct 
comparisons.    The CaR4 MIN6 cell clone was therefore used for further studies of the 
effects of CaR down-regulation on MIN6 cell function. 
 
CaR and MIN6 cell proliferation  
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The incorporation of BrdU into newly synthesized DNA was used to assess the effects of 
experimental treatments on MIN6 cell proliferation, using two different methods. 
Colorimetric measurements of BrdU incorporation into populations of MIN6 cells give 
quantitative estimates of the total DNA synthesis of the population, but gives no 
information about the number of cells in the population which are in a proliferative state. 
In contrast microfluorimetric analysis of BrdU immunostaining does not give quantitative 
estimates of changes in the rate of DNA synthesis but does give direct information on 
the number of cells in the population which are actively proliferating.  Activation of the 
CaR by the calcimimetic A568 [23] in the presence of a physiological concentration 
(1.3mM) of extracellular Ca2+  ([Ca2+]o) stimulated the rate of BrdU incorporation into 
MIN6 monolayer cells (Fig. 3, upper panel). The effects of A568 on MIN6 cell 
proliferation were not concentration-dependent, as has also been reported for its  
effectson insulin secretion from islets and MIN6 cells [11], consistent with A568 acting 
allosterically to increase the affinity of the CaR for cations rather than acting as a direct 
agonist at the CaR [23]. The presence of [Ca2+]o  alone (0.5 and 2.5mM) also stimulated 
MIN6 cell proliferation as assessed by microfluorimetric analysis of  the percentage of 
the total cell population that incorporated BrdU (Fig. 3 middle panel), consistent with the 
[Ca2+]o -dependent activation of MIN6 cell p42/44 MAPK (Fig. 2) via the CaR. In 
accordance with these observations, the A568- and [Ca2+]o-dependent increases in BrdU 
incorporation were significantly (P<0.01) reduced by the presence of the p42/44 MAPK 
inhibitors PD98059 (50µM; 89±2% control, n=8) or U0126 (20µM; 78±3% control, n=8). 
The shRNA-induced down-regulation of CaR expression had no detectable effect on the 
basal rate of proliferation of MIN6 cells maintained in monolayer culture. Thus, BrdU 
incorporation into the CaR4 MIN6 cell clone was not significantly different from that of 
control cells when grown as adherent monolayers (CaR4 monolayers, 102±4% control, 
n=3, p>0.2). However, as shown in Figure 3 (lower panel) reduced CaR expression had 
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marked effects on BrdU incorporation when MIN6 cells were configured as pseudoislets, 
with CaR4 MIN6 cells showing significantly (p<0.01) reduced rates of BrdU incorporation 
when compared to control MIN6 cells (CaR4 pseudoislets, 49±5% control, n=3, p<0.01), 
consistent with a localised intra-islet function of the CaR that is not apparent when cells 
are grown as dispersed monolayers but is revealed when cells are in close apposition in 
three-dimensional structures.        
 
 
CaR and insulin secretion 
We have previously demonstrated that pharmacological activation of the CaR stimulated 
insulin secretion from MIN6 cells and from primary β-cells [11-12].  The measurements 
of insulin secretion shown in Figure 4 (upper panel) demonstrate that configuring control 
MIN6 cells as three-dimensional pseudoislets caused enhanced insulin secretory 
responses to glucose over those of equivalent cells grown as monolayers, confirming 
our previous observations [1-3]. Thus, the MIN6 cells grown as pseudoislets consistently  
showed a peak glucose-induced (20mM) insulin secretory response of approximately 
300% over basal (2mM), while the maximum response of monolayer cells was an 
approximately  80% increase.   The reduced expression of the CaR in CaR4 MIN6 cells 
had no significant effect on insulin secretion when the cells were grown as monolayers 
(CaR4 monolayers, 148±23% control, n=4, p>0.1). However, reduced CaR expression 
was associated with reduced glucose-induced insulin secretion when the cells were 
configured as pseudoislets, as shown in Figure 4 (lower panel) which compares the 
insulin secretory responses of pseudoislets formed from control MIN6 cells with those 
formed from CaR4 MIN6 cells. The role of the CaR in insulin secretion from pseudoislets 
was further investigated by exposing glucose-stimulated (20mM) pseudoislets to KCl 
(20mM) as a directly-depolarising stimulus, in contrast to glucose which is dependent 
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upon glycolytic metabolism. When expressed relative to the maximum glucose-induced 
(20mM) secretory response there was no significant difference in KCl-induced   insulin 
secretion between pseudoislets formed from control MIN6 cells or those formed from 
CaR-deficient CaR4 MIN6 cells  (control pseudoislets, 165±4% increase; CaR4 
pseudoislets 179±8%, n=4, p>0.1). 
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Discussion  
The CaR is now known to be expressed in  cell types which are not involved in systemic 
Ca2+ homeostasis, suggesting that its prime function in these cells is something other 
than the detection of circulating Ca2+ [6-8, 24, 25]. One alternative function for the CaR 
may be to detect and respond to localized rather than systemic changes in [Ca2+]o and 
the CaR has been implicated in the detection of Ca2+ concentrations in pancreatic juice 
[9] and the intestinal lumen [26], and as a mechanism through which  neuronal cells are 
influenced by the electrical activity of their near neighbours via local changes in [Ca2+]o  
[27].   We have reported previously that pancreatic endocrine cells express the CaR [10, 
11], and that its pharmacological activation stimulates secretion of insulin and glucagon 
[11,12]. The aim of the current study was to determine whether the β-cell CaR is 
involved in intra-islet cell-cell communication by detecting the localized release of 
divalent cations that are stored in β-cell secretory granules and co-released with insulin 
[13].  The obvious experimental approach of depleting insulin secretory granules of their 
cation content was not feasible because this causes a failure of secretory vesicle 
formation and disrupts the secretory process [28].  The alternative approach of using 
extracellular chelators to sequester secreted cations was also not feasible because an 
influx of [Ca2+]o is essential for normal insulin secretion. We therefore adopted the 
strategy of manipulating β-cell CaR and, in the absence of commercially-available, 
selective CaR antagonists, we used shRNA-mediated RNA interference  to manipulate 
CaR expression. Primary islets are heterogenous organs [2] and studies of cell-cell 
interactions are complicated by numerous interactions between the different islet cell 
types [2]. We have therefore developed methods to generate islet-like structures 
(pseudoislets) from the MIN6 mouse insulin-secreting cell line [29] as a simple and well-
defined model in which to study homotypic β-cell interactions [1-4, 17].  MIN6 cells have 
the additional advantage over primary β-cells of being amenable to transduction and 
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selection which facilitated the generation of stable CaR under-expressing cell lines, such 
as the CaR4 MIN6 cells used in the present study.  The reduced expression of CaR 
mRNA in these cells was accompanied by reduced functional activity of the CaR, as 
assessed by p42/44 MAPK activation, thus validating CaR4 MIN6 cells as a useful 
model for studying CaR involvement in β-cell function.  
 
CaR activation has been associated with increased proliferation in a variety of cell types, 
including fibroblasts [8], astrocytoma cells [30], and osteoblasts [31], and our results are 
consistent with a role for the CaR in the regulation of β-cell proliferation. There are 
technical difficulties associated with measurements of β-cell proliferation in primary 
islets, largely because of the very low mitotic index of primary β-cells in adult islets,  and 
MIN6 cells have been used as substitutes in several studies of β-cell proliferation [18, 
32-34].  Proliferative MIN6 cells constitutively over-express the SV40 large T antigen [29] 
which de-regulates their cell cycle [29]. However, the results of the current study and 
previous studies [34, 35] demonstrate that at least part of the MIN6 cell proliferative 
capacity is regulated by extracellular signals, validating this experimental model. In the 
present study, pharmacological activation of the CaR stimulated MIN6 cell proliferation 
and this was due, at least in part, to an increase in the number of cells in the proliferative 
state. The CaR-induced increase in MIN6 cell proliferation was associated with 
activation of the p42/44 MAPK pathway which has been implicated in cell-cycle 
regulation in a wide variety of mammalian tissues [38-40], including MIN6 cells [18]. Our 
results demonstrated that the presence of [Ca2+]o was alone sufficient to activate p42/44 
MAPK and enhance MIN6 cell proliferation, consistent with reports in other cell types 
that elevated  [Ca2+]o can activate p42/44 [36] and increase cell proliferation [37]. The 
current results also show that further pharmacological activation of CaR using an 
allosteric activator (A568) enhanced MIN6 cell proliferation at a physiological 
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concentration of [Ca2+]o.  The involvement of p42/44 MAPK in transducing signals from 
the β-cell CaR was confirmed by the inhibitory effects of two pharmacological agents, 
PD98059 and UO126, both of which inhibit the activity of the mitogen-activated ERK-
activating kinase (MEK) which is upstream of the p42/44 MAPKs.  These observations 
are consistent with our previous report that CaR-dependent stimulation of insulin 
secretion from MIN6 pseudoislets was associated with the activation of p42/44 MAPK 
and was inhibited by the presence of MEK inhibitors [11], and suggest that transduction 
through p42/44 MAPK cascade is central to the effects of CaR activation on β-cell 
function.  
 
The reduced levels of CaR expression in CaR4 MIN6 cells did not influence their 
proliferative capacity when the cells were grown as monolayers, suggesting that the 
levels of CaR expression per se do not affect the growth rate of MIN6 cells. However, 
the CaR-depleted cells showed significantly reduced rates of proliferation when 
configured as pseudoislets, consistent with signalling through the CaR being involved in 
the regulation of β-cell proliferation in situations where the cells are sufficiently close to 
communicate by localized release of an endogenous CaR activator (i.e. pseudoislets), 
but not where the cells are anatomically separate (i.e. monolayers).  Thus, the current 
studies of CaR involvement in β-cell proliferation are consistent with a model in which β-
cells within islet-like structures influence neighbouring β-cells by releasing an 
endogenous activator of the CaR (Ca2+, other divalent cations) which increases the 
proliferative capacity of neighbouring β-cells through CaR activation of the p42/44 MAPK 
cascade. The physiological significance of this proposed mechanism is uncertain, but 
the β-cell mass increases at times of increased demand for insulin [41, 42], and CaR 
activation by divalent cations co-released with insulin offers one mechanism through 
 16 
which β-cells can monitor their own secretory activity (autocrine) and that of 
neighbouring β-cells (paracrine) and adjust their proliferative potential accordingly.  
 
The results of this study also suggest an important role for the β-cell CaR in integrating 
the secretory responses of β-cells in islet-like structures. Thus, insulin secretion from 
individual MIN6 cells was not affected by manipulating the levels of CaR expression, 
suggesting that CaR expression is not an important regulator of signal recognition in β-
cells. However, previous studies have shown that CaR activation is alone sufficient to 
trigger insulin secretion [11, 12],  and our experiments demonstrated that down-
regulation of CaR expression prevented the improvement of insulin secretory responses 
when MIN6 cells were configured as islet-like structures, consistent with CaR activation 
being an important means of intra-islet communication. Individual -cells are 
heterogenous and differ in their sensory [43], biosynthetic [44, 45], intracellular Ca2+ [21] 
and secretory [46] responses to external stimuli. CaR activation by secreted cations 
offers one mechanism through which an activated -cell could activate less-sensitive 
neighbouring cells, and thus enable a heterogenous population of cells to mount an 
integrated response to external signals [2]. A recruiting role for the CaR in islet-like 
structures is further supported by our observation that CaR down-regulation had no 
effect on secretory responses of MIN6 pseudoislets to high extracellular K+, a stimulus 
that bypasses normal metabolic processes and directly activates all the pseudoislet 
cells.   
 
In conclusion, it is well established that normal islet function is dependent on 
communication between islet cells [2] and the results of this study suggest that β-cell to 
β-cell interactions via the CaR are one mechanism of this communication.    
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Figure Legends 
 
Figure 1: Down-regulation of CaR mRNA expression by shRNA. 
MIN6 cells were stably transduced with lentiviral particles containing shRNA constructs 
against CaR (CaR 2 and CaR 4) or control constructs (non-shRNA control) and CaR 
mRNA expression was measured by quantitative PCR. The CaR4 shRNA induced a 
marked reduction (P<0.01) in CaR mRNA compared to non-transduced MIN6 cells (non-
transduced control) or to cells transduced with non-shRNA containing lentivirus (non-
shRNA control). In contrast, the CaR2 shRNA construct did not induce a significant 
reduction in CaR mRNA expression (p>0.2).  The results are expressed relative to copy 
number for actin mRNA in the same extracts. Data are means + SEM, n=3. ***p<0.01 vs 
both control samples. 
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Figure 2: Decreased signalling through CaR in shRNA CaR4 expressing MIN6 
cells.  
The Figure shows immunoblot analysis of phosphorylated p42/44 MAPK (A,C,E) and  
total immunoreactive p42/44 MAPK (B,D,F) in control MIN6 cells (A, B,E,F) or in CaR4-
transduced MIN6 cells (C,D,E,F).  
[A, B] Incubation of control MIN6 cells in the presence of  Ca2+ (1.3mM) in the absence 
(lane 3) or presence of 0.1 µM A568 (lane 4) induced a rapid increase in the 
phosphorylation of p42/44 MAPK (panel A), that was inhibited by the presence of the 
MEK inhibitors PD98059 (50 M) or UO126 (20 M), consistent with a CaR-dependent 
activation of p42/44 MAPK.  The membrane was stripped and re-probed with an 
antibody against total p42/44 MAPK immunoreactivity (panel B).  
[C, D] In CaR4 shRNA transduced cells the effects of Ca2+ in the absence (lane 3) or 
presence of 0.1 µM A568 (lane 4) on p42/44 MAPK phosphorylation were much 
reduced, consistent with the down-regulation of functional CaR expression in this MIN6 
cell clone. Panel D shows total p42/44 MAPK immunoreactivity in the samples from 
panel C. Results show one experiment typical of three. 
[E,F] These blots show phosphorylated p42/44 MAPK (E) or total p42/44 (F) in extracts 
from control MIN6 cells (lanes 1,3,5) or CaR4 MIN6 cells (lanes 2,4,6) to allow direct 
comparisons between control and CaR-depleted cells.  The presence of  Ca2+ (1.3mM) 
in the absence (lanes 3,4) or presence of 0.1 µM A568 (lanes 5,6) induced a rapid 
increase in the phosphorylation of p42/44 MAPK in control MIN6 cells (lanes 3,5), but 
this was much reduced in CaR4 shRNA transduced cells (lanes 4,6). 
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Figure 3: CaR activation and MIN6 cell proliferation 
MIN6 cell proliferation was assessed by measuring the incorporation of BrdU into newly-
synthesized DNA using an anti-BrdU antibody. 
Upper panel: BrdU incorporation into MIN6 populations. 
MIN6 cells grown as monolayers in 96 well tissue culture plates were incubated for 2.5 
hours in serum-free culture medium containing 5.5mM glucose in the presence of 10μM 
BrdU and different concentrations of the calcimimetic A568, as shown. BrdU 
incorporation was assessed by colorimetric assay using an HRP-linked anti-BrdU 
antibody. Data are expressed as percentage of the basal BrdU incorporation into cells 
incubated in serum-free/5.5mM glucose culture medium, in the absence of A568. Bars 
show means+SEM, n=8. *** P<0.01 versus basal proliferation.  The Figure shows one 
experiment typical of three separate experiments. 
Middle panel: BrdU incorporation into individual MIN6 cells. 
MIN6 cells grown as monolayers on glass coverslips were incubated for three hours in 
medium containing various concentrations of Ca2+, as shown,  with  BrdU (10μM) being  
present for the final two hours of the incubation.  Fluorescence microscopy was used to 
detect BrdU incorporation into MIN6 cell DNA using an Alexa 594-conjugated -
conjugated anti-BrdU antibody. A minimum of 100 cells were counted on each coverslip 
and results are expressed as the percentage of the total number of cells which showed 
positive nuclear immunofluorescence for BrdU. Bars show mean+SEM for 6 different 
coverslips. ** P<0.05, *** P<0.01 versus absence of Ca2+.  
Lower panel: CaR downregulation reduced proliferation in MIN6 pseudoislets 
CaR4-transduced MIN6 cells showed no changes in BrdU incorporation compared to 
control MIN6 cells when grown as monolayers (p>0.2). However, configuring the CaR4 
MIN6 cells as pseudoislets caused a significant reduction in BrdU incorporation when 
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compared to control MIN6 cells configured as pseudoislets. Bars show means+SEM, 
n=3, ***p<0.01.     
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Figure 4: Effects of CaR down-regulation on insulin secretion 
Upper panel: Effect of cell configuration on insulin secretion  
Control (non-shRNA vector transduced) MIN6 cells configured as monolayers (○) or as 
pseudoislets (●) were perifused with buffer containing 2mM glucose for 10 minutes (0-10 
min) to achieve a basal rate of secretion, after which they were exposed to a buffer 
containing 20mM glucose. Cells configured as pseudoislets showed significantly 
(p<0.001) enhanced secretory responses when compared to equivalent cells maintained 
as monolayers. Secretion is expressed as a percentage of basal (2mM glucose) 
secretion. Points show means ± SEM, n=4, and statistical analysis compares areas 
under the curves between groups. 
 
Lower panel: Effects of CaR down-regulation on insulin secretion from pseudoislets.   
Pseudoislets formed from control (●) or CaR-depleted (○) CaR4  MIN6 cells were 
perifused with buffer containing 2mM glucose for 10 minutes (0-10 min), after which they 
were exposed to a buffer containing 20mM glucose. Insulin secretion from the CaR4 
pseudoislets was significantly less (p<0.001) than from control pseudoislets,   Secretion 
is expressed as a percentage of basal (2mM glucose) secretion. Points show means ± 
SEM, n=4.  
